The GLP-1 journey: from discovery science to therapeutic impact
Daniel J. Drucker
Abstract
Over several decades the JCI has published key advances in our understanding of glucagon-like peptide 1 (GLP-1) biology.The first incretin peptide characterized in the 1970s, glucose-dependent insulinotropic polypeptide (GIP), was isolated from porcine gastric extracts.Subsequently, the sequence of GLP-1 was identified following the cloning of the glucagon cDNAs and genes, soon followed by the demonstration that GLP-1 potentiated glucosedependent insulin secretion in cells, animals, and humans (comprehensively reviewed in Drucker, et al.; ref. 1).
Topics & Concepts
Drug discoveryMEDLINEData scienceMedicineComputational biologyBioinformaticsComputer scienceBiologyBiochemistryDiabetes Treatment and ManagementPancreatic function and diabetesMetabolism, Diabetes, and Cancer